Medotrax

DIGITAL INFRASTRUCTURE FOR ALZHEIMER’S DISEASE

Connected intelligence for Alzheimer’s research and care.

Connecting cognitive assessment, neuroimaging and real-world data for earlier detection and scalable research.

Explore BraincheXExplore MRI Platform
Clinical insightScientific rigourDigital execution

CONNECTED PRODUCTS

Build consistent cognitive and imaging workflows.

Deploy each product independently or connect both within programme-specific research and care pathways.

Digital cognitive assessment

BraincheX

A multidomain digital test battery for structured assessment in research, screening and implementation programmes.

Standardised administrationDecentralised deploymentStructured research outputsEvidence-led development
Explore BraincheXDiscuss your study →
Neuroimaging infrastructure

MRI Data Processing Platform

A secure cloud workflow for DICOM ingestion, de-identification, quality control, automated processing and standardised outputs.

Multicentre operationsTraceable processingReproducible pipelinesScalable compute
Explore MRI PlatformDiscuss your workflow →

THE CONNECTING LAYER

Bring assessment, imaging and programme data together.

Medotrax Hub supports connected longitudinal workflows without blurring the distinct roles of screening, diagnosis and monitoring.

MEDOTRAXHUB
Cognitive dataBraincheX results and trajectories
Imaging dataMRI inputs, quality and outputs
Programme dataStructured multicentre workflows
EvidenceResearch-ready review and export

RESEARCH & IMPLEMENTATION

Technology in real-world programmes.

Digital assessment and MRI infrastructure supporting earlier detection, inclusive recruitment, multicentre imaging and research-ready real-world data.

01
Healthcare system preparednessActive

COGSCREEN II

Scale earlier Alzheimer’s detection.

BraincheX and blood-based biomarkers are being evaluated across primary and specialist care in Munich.

Medotrax contributionBraincheX for standardised assessment, workflow integration and real-world evaluation.
For research partnersReproducible workflows for participant identification, biomarker pathways and implementation studies.
View studyDiscuss BraincheX →
02
Inclusive early detectionActive

AD-RIDDLE

Reach more people through inclusive detection.

The Munich programme connects community engagement, adaptable digital assessment, biomarkers and specialist follow-up.

Medotrax contributionA platform for standardised, pseudonymised and culturally adaptable cognitive assessment.
For research partnersMore inclusive recruitment, consistent data collection and implementation evidence across diverse populations.
Visit projectPlan your programme →
03
Connected Alzheimer’s care2026–2031

ACCESS-AD

Scale connected Alzheimer’s care.

ACCESS-AD integrates diagnostics, monitoring and real-world evidence to support timely and equitable access across Europe.

Medotrax contributionSelected BraincheX and MRI workflows may support the programme, subject to final scope agreement.
For research partnersConnected cognitive and imaging workflows for harmonised multicentre data and scalable monitoring.
Visit projectConnect your workflow →
04
Real-world MRI dataOxford · Cambridge

FOR-REAL

Make real-world MRI data research-ready.

FOR-REAL supports structured clinical and MRI data collection for the InRAD registry in memory clinics.

Medotrax contributionSecure DICOM upload, de-identification, quality control, automated processing and standardised outputs.
For research partnersConvert routine scans into traceable, analysis-ready datasets and simplify multicentre operations.
Explore InRADDiscuss your MRI study →
05
Community-based detection14 pharmacies · Munich

DARE

Bring cognitive assessment closer to the community.

DARE evaluates pharmacy-based digital cognitive assessment and structured referral pathways for adults aged 60 and older.

Medotrax contributionTablet-based cognitive testing and structured data collection across decentralised community settings.
For research partnersReach community populations, collect consistent multisite data and evaluate feasibility, acceptance and referral pathways.
Explore DAREDiscuss community screening →

PUBLISHED EVIDENCE

Promising performance in early Alzheimer’s disease.

A 2026 pilot study compared BraincheX with CERAD-Plus in 56 participants and reported strong discrimination between early Alzheimer’s disease and amyloid-negative controls.

Read publication
0.86AUC
89.7%Sensitivity
0.84Cronbach’s alpha
0.73Correlation with CERAD total

BraincheX supports cognitive screening and assessment. It does not replace a comprehensive clinical diagnosis. Findings require confirmation in larger, independent and more diverse cohorts.

START A CONVERSATION

Tell us what you are building.

Discuss BraincheX, MRI processing or an integrated research workflow. Do not submit patient data, medical records or imaging files.

Email Medotraxinfo@medotrax.com